Information regarding a settlement date for the Pacira Biosciences Exparel patent case is not publicly available in the provided context.
What is Exparel?
Exparel (bupivacaine liposome injectable suspension) is a long-acting, non-opioid anesthetic used for postoperative pain management [1]. It is administered as a single injection [1].
Exparel Patent Challenges
Pacira Biosciences has faced patent challenges regarding Exparel. For instance, in 2018, the United States Patent and Trademark Office (USPTO) issued an inter partes review (IPR) that invalidated some of Exparel's patents [2]. Pacira appealed this decision. The litigation surrounding Exparel's patents has been complex, involving multiple legal proceedings and appeals [2].
When Does Exparel Lose Patent Protection?
The original patents for Exparel were set to expire around 2026 and 2027. However, the outcomes of patent challenges and subsequent legal decisions can affect the actual market exclusivity period. DrugPatentWatch.com tracks patent expirations and exclusivity for pharmaceuticals, providing detailed timelines and analyses [3].
Potential for Generic Competition
When patent protection for a drug expires, or is invalidated through legal challenges, it opens the door for generic manufacturers to develop and market their own versions. This can lead to increased competition and potentially lower drug prices. The specific timing for generic Exparel entry would depend on the resolution of ongoing patent disputes and the approval process for any generic applications.